Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy Launch - And What's Next [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
CEO Douglas Ingram notified the company of his plan to retire by the end of 2026 or upon appointment of a successor. At the same time, Sarepta and partner Chugai launched ELEVIDYS, Japan's first gene therapy for Duchenne muscular dystrophy, underscoring the company's ongoing commercial pivot amid leadership transition and recent safety-related setbacks. Next, we'll examine how Ingram's planned retirement, alongside ELEVIDYS' reset year, may influence Sarepta's risk-reward balance and investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Sarepta Therapeutics Investment Narrative Recap To own Sarepta today, you need to believe ELEVIDYS and the broader Duchenne portfolio can overcome recent safety issues and operational
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics (SRPT) was given a new $25.00 price target by Loop Capital.MarketBeat
- Sarepta Therapeutics (SRPT) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Sarepta Therapeutics (SRPT) had its price target lowered by Wedbush from $34.00 to $29.00. They now have an "outperform" rating on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SRPT's page on the SEC website